Pharvaris (PHVS) Projected to Post Quarterly Earnings on Tuesday

Pharvaris (NASDAQ:PHVS) is projected to issue its Q4 2025 results before the market opens on Tuesday, April 14th. Analysts expect the company to announce earnings of ($0.69) per share for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, April 9, 2026 at 12:30 PM ET.

Pharvaris Stock Performance

PHVS stock opened at $26.63 on Monday. The stock’s fifty day simple moving average is $27.05 and its two-hundred day simple moving average is $25.53. Pharvaris has a 1-year low of $11.66 and a 1-year high of $29.85. The stock has a market cap of $1.74 billion, a P/E ratio of -7.90 and a beta of -2.58.

Analysts Set New Price Targets

PHVS has been the topic of several research analyst reports. HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Pharvaris in a research report on Tuesday, March 3rd. Royal Bank Of Canada cut their price objective on Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a research report on Monday, April 6th. Wedbush boosted their price objective on Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 7th. Wolfe Research initiated coverage on Pharvaris in a research report on Thursday. They issued an “outperform” rating and a $42.00 price objective on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a research report on Thursday, January 22nd. Eleven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Pharvaris currently has an average rating of “Moderate Buy” and an average price target of $42.73.

More Pharvaris News

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Wolfe Research initiated coverage with an “Outperform” rating and a $42 price target (~58% upside vs. current levels), which can boost investor interest and buying pressure. Wolfe Research initiates coverage of Pharvaris NV (PHVS) with outperform recommendation
• Positive Sentiment: Wedbush raised its price target on PHVS to $42, aligning with other bullish voices and reinforcing the street’s constructive view on Pharvaris’ growth/valuation runway. Wedbush Increases Pharvaris (NASDAQ:PHVS) Price Target to $42.00
• Neutral Sentiment: HC Wainwright published earnings/long‑term model commentary for Pharvaris (estimating FY2030 figures and Q1 outlook). Analyst model updates can influence expectations but are not an immediate catalyst absent new clinical or commercial data. HC Wainwright Predicts Pharvaris FY2030 Earnings
• Neutral Sentiment: Reported short-interest data is effectively zero (no measurable short volume), so short-covering or squeeze dynamics are unlikely to be a driver in the near term. (Internal reporting entry.)
• Negative Sentiment: CEO Berndt Modig sold 23,333 shares (~14.1% reduction in his reported position) under a pre-arranged Rule 10b5-1 plan for proceeds ~ $647k. Insider sales can be interpreted negatively by some investors even when executed under 10b5-1 plans. SEC filing for insider sale

Insider Activity at Pharvaris

In other news, CEO Berndt Modig sold 23,333 shares of the company’s stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $27.74, for a total transaction of $647,257.42. Following the transaction, the chief executive officer owned 142,084 shares of the company’s stock, valued at $3,941,410.16. This represents a 14.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Occudo Quantitative Strategies LP purchased a new position in shares of Pharvaris during the 4th quarter valued at $343,000. Virtus Investment Advisers LLC lifted its holdings in Pharvaris by 66.7% during the 4th quarter. Virtus Investment Advisers LLC now owns 11,011 shares of the company’s stock worth $306,000 after purchasing an additional 4,407 shares in the last quarter. Schroder Investment Management Group purchased a new stake in Pharvaris during the 3rd quarter worth about $293,000. Boothbay Fund Management LLC purchased a new stake in Pharvaris during the 2nd quarter worth about $285,000. Finally, Two Sigma Investments LP purchased a new stake in Pharvaris during the 3rd quarter worth about $265,000.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.